Iodine-131-SGMIB anti-HER2 monoclonal antibodyAlternative Names: 131I-SGMIB anti-HER2-VHH1; [131I]-SGMIB Anti-HER2 VHH1; CAM-H2; Iodine-131-SGMIB anti-HER2 VHH1
Latest Information Update: 24 Feb 2016
At a glance
- Originator Camel-IDS
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Immunomodulators; Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 01 Feb 2016 Preclinical trials in Breast cancer in Belgium (Parenteral) before February 2016
- 01 Feb 2016 Phase-I clinical trials in Breast cancer (Diagnosis) in Belgium (Parenteral) (NCT02683083)